SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-21-000043
Filing Date
2021-09-15
Accepted
2021-09-15 16:07:20
Documents
12
Period of Report
2021-09-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20210915.htm   iXBRL 8-K 47042
  Complete submission text file 0001438533-21-000043.txt   189500

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20210915.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20210915_lab.xml EX-101.LAB 25154
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20210915_pre.xml EX-101.PRE 13044
5 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20210915_htm.xml XML 11256
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 211255504
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences